PharmaLex expands pricing & reimbursement and health economics platform with EBMA Consulting merger

PharmaLex expands pricing & reimbursement and health economics platform with EBMA Consulting merger
 
Merger strengthens market access expertise

Frankfurt, Germany – March 9, 2022: PharmaLex Group, a leading provider of specialized services for the pharma, biotech and medtech industries worldwide, has announced a merger with Italy-based EBMA Consulting, a specialist consultancy company focused on strategic pricing, market access and health economics services for the life sciences.

Founded in 2010 by Gianluca Furneri, EBMA Consulting has many years of practical experience in health economics, pricing and market access and serves small and mid-sized pharmaceutical companies in Italy as well as  the rest of Europe and the U.S. 

EBMA Consulting specializes in offering general market access insights, providing market access development strategies and supporting customers with communicating the value of their products through health technology assessments to key stakeholders.

“The merger with PharmaLex creates the opportunity to provide a Europe-wide market access platform within PharmaLex, while also paving the way to developing a global community in market access,” Gianluca said. “With our shared commitment to solutions to meet the challenges our clients face, the merger between EBMA Consulting and PharmaLex will help clients address the pricing and reimbursement challenges they often face when negotiating with payers. I am very happy to join and support PharmaLex’s group of consultants to expand the combined market access service offering.”

“We are delighted to welcome Gianluca and his incredibly talented team of experts to the PharmaLex Group.  Together with PharmaLex Italy and MA Provider, another recent merger, EBMA strengthens our market access services to provide comprehensive, strategic and operational support, to successfully secure market access in the EU and set the basis to reach their commercial objectives,” said PharmaLex CEO Dr. Thomas Dobmeyer. “EBMA has an outstanding track record developing bespoke approaches to meet the market access requirements of clients, supported by solid analytical capabilities. This approach fits seamlessly with our vision and values at PharmaLex to always provide quality services and outstanding solutions to exceed our customers’ expectations.”